Open Access Open Access  Restricted Access Subscription Access

Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden


Affiliations
1 Department of Respiratory Medicine, Gavle Hospital, 80187 Gavle, Sweden
2 Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Solna, Stockholm, Sweden
3 Centre for Research and Development, Uppsala University, County Council of Gavleborg, Gavle, Sweden
 

An increasing proportion of cancer patients are aged>65 years and many are aged >70 years. Treatment of the elderly with lung cancer has, therefore, become an important issue; so we performed a retrospective study of our patients to demonstrate how elderly patients with NSCLC are treated in real-life, clinical practice. All patients aged ≥70 years with NSCLC at our department were reviewed retrospectively. In total, 1059 patients (50.8% of all NSCLCpatients). Of these patients, 243 (22.9%) received chemotherapy, 164 (70.4%) of whom were treated with a platinum doublet using carboplatin. Second- and third-line chemotherapy were given to 31.4% and 13.9% of patients, respectively. Median overall survival was 289 and 320 days for male and female patients, respectively. Patients with performance status (PS) 0 experienced significantly better survival than patients with PS1 or PS 2: 410, 314, and 204 days, respectively. Age was of less importance, with patients aged 70-79 years versus those aged ≥80 years. Treatment of elderly NSCLC patients with chemotherapy is feasible if they have a good PS and appears to prolong survival. In this study, we found no significant differences in survival either between age groups or genders.
User
Notifications
Font Size

Abstract Views: 92

PDF Views: 0




  • Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden

Abstract Views: 92  |  PDF Views: 0

Authors

Hirsh Koyi
Department of Respiratory Medicine, Gavle Hospital, 80187 Gavle, Sweden
Gunnar Hillerdal
Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Solna, Stockholm, Sweden
Olov Andersson
Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Solna, Stockholm, Sweden
Karl-Gustav Kölbeck
Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Solna, Stockholm, Sweden
Per Liv
Centre for Research and Development, Uppsala University, County Council of Gavleborg, Gavle, Sweden
Eva Branden
Department of Respiratory Medicine, Gavle Hospital, 80187 Gavle, Sweden

Abstract


An increasing proportion of cancer patients are aged>65 years and many are aged >70 years. Treatment of the elderly with lung cancer has, therefore, become an important issue; so we performed a retrospective study of our patients to demonstrate how elderly patients with NSCLC are treated in real-life, clinical practice. All patients aged ≥70 years with NSCLC at our department were reviewed retrospectively. In total, 1059 patients (50.8% of all NSCLCpatients). Of these patients, 243 (22.9%) received chemotherapy, 164 (70.4%) of whom were treated with a platinum doublet using carboplatin. Second- and third-line chemotherapy were given to 31.4% and 13.9% of patients, respectively. Median overall survival was 289 and 320 days for male and female patients, respectively. Patients with performance status (PS) 0 experienced significantly better survival than patients with PS1 or PS 2: 410, 314, and 204 days, respectively. Age was of less importance, with patients aged 70-79 years versus those aged ≥80 years. Treatment of elderly NSCLC patients with chemotherapy is feasible if they have a good PS and appears to prolong survival. In this study, we found no significant differences in survival either between age groups or genders.